title: PCV for anaplastic oligodendrogliomas: back to the future or a step backwards? A point/counterpoint discussion.
authors.affiliation: Department of Internal Medicine and Markey Cancer Center, University of Kentucky, Lexington, KY, USA.
authors.forename: J Lee
authors.initials: JL
authors.lastname: Villano
authors.forename: Patrick Y
authors.initials: PY
authors.lastname: Wen
authors.forename: Eudocia Q
authors.initials: EQ
authors.lastname: Lee
authors.forename: Lakshmi
authors.initials: L
authors.lastname: Nayak
authors.forename: David A
authors.initials: DA
authors.lastname: Reardon
authors.forename: Myrna R
authors.initials: MR
authors.lastname: Rosenfeld
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage / Q000009:adverse effects; D009837:Oligodendroglioma / Q000188:drug therapy*; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine